Brokerages Set BioAtla, Inc. (NASDAQ:BCAB) Target Price at $4.00

Shares of BioAtla, Inc. (NASDAQ:BCAB) have earned an average recommendation of “Hold” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $4.00.

A number of equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAtla in a report on Friday, January 9th. Rodman & Renshaw started coverage on shares of BioAtla in a research report on Tuesday. They set a “buy” rating and a $4.00 price target on the stock.

Institutional Investors Weigh In On BioAtla

A number of hedge funds and other institutional investors have recently made changes to their positions in BCAB. Sheets Smith Investment Management bought a new stake in shares of BioAtla in the third quarter valued at approximately $46,000. Woodline Partners LP acquired a new position in BioAtla in the 1st quarter valued at $26,000. Susquehanna International Group LLP raised its holdings in BioAtla by 237.6% in the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after acquiring an additional 177,760 shares in the last quarter. Millennium Management LLC bought a new stake in shares of BioAtla during the 3rd quarter valued at $235,000. Finally, Acadian Asset Management LLC grew its holdings in shares of BioAtla by 968.9% during the 1st quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after purchasing an additional 1,531,994 shares in the last quarter. 77.23% of the stock is currently owned by institutional investors and hedge funds.

BioAtla Price Performance

BioAtla stock opened at $0.32 on Tuesday. The company’s 50-day moving average is $0.72 and its 200-day moving average is $0.60. The firm has a market capitalization of $18.79 million, a PE ratio of -0.28 and a beta of 1.04. BioAtla has a fifty-two week low of $0.24 and a fifty-two week high of $1.43.

BioAtla (NASDAQ:BCAB) last issued its earnings results on Thursday, November 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.04. As a group, analysts expect that BioAtla will post -1.46 EPS for the current year.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.